Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-09
- Target Recruit Count
- 89
- Registration Number
- NCT05950997
- Locations
- 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjin, Jiangsu, China
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT05943496
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
- Conditions
- Refractory B-Cell Non-Hodgkin LymphomaRefractory Aggressive B-cell LymphomasAggressive B-cell NHLDe Novo or Transformed Indolent B-cell LymphomaHigh-Grade B-Cell Lymphoma, NosGrade 3b Follicular LymphomaT Cell/Histiocyte-rich Large B-cell LymphomaC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)DLBCL, Nos Genetic Subtypes
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Patrick C. Johnson, MD
- Target Recruit Count
- 27
- Registration Number
- NCT05583149
- Locations
- 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT05557695
- Locations
- 🇬🇧
Research Site, Wigan, United Kingdom
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05495464
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 33
- Registration Number
- NCT05388006
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 52
- Registration Number
- NCT05336812
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05256641
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
- Conditions
- Interventions
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 650
- Registration Number
- NCT05197192
- Locations
- 🇩🇪
Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany
🇩🇪DRK Kliniken Berlin Köpenick, Berlin, Germany
🇩🇪Helios Klinikum Bad Saarow, Bad Saarow, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.